A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Authors :: Satoko Kakiuchi-Kiyota
Thorsten Ross
Heidi Ackerly Wallweber
James R. Kiefer
Melissa M. Schutten
Adeyemi O. Adedeji
Hao Cai
Robert Hendricks
Sivan Cohen
Srividya Myneni
Luna Liu
Aaron Fullerton
Nicholas Corr
Lanlan Yu
Denise de Almeida Nagata
Shelly Zhong
Steven R. Leong
Ji Li
Rin Nakamura
Teiko Sumiyoshi
Jinze Li
Ayse Meric Ovacik
Bing Zheng
Mike Dillon
Christoph Spiess
Susanne Wingert
Erich Rajkovic
Kristina Ellwanger
Uwe Reusch
Andrew G. Polson
Source :: Leukemia. 36(4)
Publication Year :: 2021
Abstract: Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate cell engager (ICE

Subjects :: Cancer Research
Oncology
Phagocytosis
Antibodies, Bispecific
Receptors, IgG
Humans
Hematology
B-Cell Maturation Antigen
Multiple Myeloma

Tools